​
​

Marker Therapeutics (MRKR) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChart

Marker Therapeutics Revenue Highlights

Latest Revenue (Y)

$3.31M

Latest Revenue (Q)

$1.93M

Main Segment (Y)

Related Party Service

Marker Therapeutics Revenue by Period

Marker Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$3.31M-63.23%
2022-12-31$9.00M625.17%
2021-12-31$1.24M166.01%
2020-12-31$466.79K118.95%
2019-12-31$213.19K3.50%
2018-12-31$205.99K100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31-100.00%
2009-12-31-100.00%
2008-12-31-100.00%
2007-12-31-100.00%
2006-12-31-100.00%
2005-12-31-100.00%
2004-12-31-100.00%
2003-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31$25.05K-79.25%
1999-12-31$120.72K-

Marker Therapeutics generated $3.31M in revenue during NA 2023, up -63.23% compared to the previous quarter, and up 1607.39% compared to the same period a year ago.

Marker Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$1.93M64.72%
2024-06-30$1.17M-6.01%
2024-03-31$1.24M17.75%
2023-12-31$1.06M310.13%
2023-09-30$257.61K-66.22%
2023-06-30$762.66K-78.21%
2023-03-31$3.50M-42.19%
2022-12-31$6.05M105.24%
2022-09-30$2.95M272.95%
2022-06-30$791.00K-17.95%
2022-03-31$964.00K-22.37%
2021-12-31$1.24M100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--100.00%
2020-12-31$215.00100.00%
2020-09-30--100.00%
2020-06-30$466.79K100.00%
2020-03-31--100.00%
2019-12-31$213.19K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$6.00100.00%
2018-09-30--100.00%
2018-06-30$205.99K100.00%
2018-03-31-100.00%
2017-12-31--100.00%
2017-09-30$183.06K100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-10-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31-100.00%
2007-12-31--

Marker Therapeutics generated $1.93M in revenue during Q3 2024, up 64.72% compared to the previous quarter, and up 252.54% compared to the same period a year ago.

Marker Therapeutics Revenue Breakdown

Marker Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Related Party Service$3.50M----
Service$816.64K$5.50M---
Grant-$3.51M$466.79K$213.19K-
Grant income--$1.24M--

Marker Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Related Party Service (81.08%), and Service (18.92%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.93M$1.17M$1.24M$1.23M$759.14K$999.57K$213.19K---
Service----$3.50M$2.55M----
Grant income-------$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Grant (100.00%).

Marker Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.23M$759.14K$999.57K$213.19K--
Service$3.50M$2.55M----
Grant income---$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Service (73.93%), and Grant (26.07%).

Marker Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AGENAgenus$156.31M$25.11M
ALECAlector$97.06M$15.08M
AADIAadi Bioscience$24.35M$7.21M
IKNAIkena Oncology$9.16M-
MRKRMarker Therapeutics$3.31M$1.93M
LUMOLumos Pharma$2.05M$488.00K
CBIOGyre Therapeutics$794.00K-
KROSKeros Therapeutics$151.00K$37.00K
ANEBAnebulo Pharmaceuticals--
XCURExicure--
BNOXBionomics--
AVTEAerovate Therapeutics--
RNXTRenovoRx--
TPSTTempest Therapeutics--
ACRVAcrivon Therapeutics--
PMVPPMV Pharmaceuticals--
PTIXProtagenic Therapeutics-$50.29K
EWTXEdgewise Therapeutics--

MRKR Revenue FAQ

What is Marker Therapeutics’s yearly revenue?

Marker Therapeutics's yearly revenue for 2023 was $3.31M, representing a decrease of -63.23% compared to 2022. The company's yearly revenue for 2022 was $9M, representing an increase of 625.17% compared to 2021. MRKR's yearly revenue for 2021 was $1.24M, representing an increase of 166.01% compared to 2020.

What is Marker Therapeutics’s quarterly revenue?

Marker Therapeutics's quarterly revenue for Q3 2024 was $1.93M, a 64.72% increase from the previous quarter (Q2 2024), and a 647.66% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.17M, a -6.01% decrease from the previous quarter (Q1 2024), and a 53.31% increase year-over-year (Q2 2023). MRKR's quarterly revenue for Q1 2024 was $1.24M, a 17.75% increase from the previous quarter (Q4 2023), and a -64.46% decrease year-over-year (Q1 2023).

What is Marker Therapeutics’s revenue growth rate?

Marker Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 166.66%, and for the last 5 years (2019-2023) was 1453.11%.

What are Marker Therapeutics’s revenue streams?

Marker Therapeutics's revenue streams in c 23 are Related Party Service, and Service. Related Party Service generated $3.5M in revenue, accounting 81.08% of the company's total revenue Service generated $816.64K in revenue, accounting 18.92% of the company's total revenue, down -85.15% year-over-year.

What is Marker Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Marker Therapeutics was Related Party Service. This segment made a revenue of $3.5M, representing 81.08% of the company's total revenue.